ArticleProceedings of the National Academy of Sciences of the United States of America2020
Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6
Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 55 citations in OpenAlex.
- IgA2Cell reports. Medicine · 2025Trial
- Protein biomarkers of inflammation in women with SLE and their newborn children.Lupus science & medicine · 2026Article
- Review
- Thymus and Leishmania at the Crossroads: Autoimmunity and Cancer.Immunology · 2026Review
- Female mice with a Xist deletion in B cells can develop lupus-associated phenotypes.Cell reports · 2026Article
- Integrated metabolomic and cytokine profiling reveals biomarkers across the clinical spectrum of lupus nephritis.Frontiers in immunology · 2026Article
- Interleukin-10 at the crossroads of immunity in TLR7-induced lupus.Frontiers in immunology · 2026Article
- Interleukin-10 family cytokines: key regulators and novel therapeutic targets for respiratory diseases.Inflammopharmacology · 2025Review
- The fourth trimester and challenges for the lupus patient.EULAR rheumatology open · 2025Review
- Rewired type I IFN signaling is linked to age-dependent differences in COVID-19.Cell reports. Medicine · 2025Article
- Cytokine networks and therapeutic advances in systemic lupus erythematosus.Frontiers in immunology · 2025Review
- Review
- Brain-immune interactions: implication for cognitive impairments in Alzheimer's disease and autoimmune disorders.Journal of leukocyte biology · 2024Review
- Occurrence and role of Tph cells in various renal diseases.Molecular medicine (Cambridge, Mass.) · 2024Review
- Potential of resveratrol in the treatment of systemic lupus erythematosus (Review).Molecular medicine reports · 2024Review
- Cytokines in Follicular Helper T Cell Biology in Physiologic and Pathologic Conditions.Immune network · 2024Review
- T follicular helper cells and T follicular regulatory cells in autoimmune diseases.Frontiers in immunology · 2023Review
- Article
- Salivary IgA subtypes as novel disease biomarkers in systemic lupus erythematosus.Frontiers in immunology · 2023Article
- Human umbilical cord mesenchymal stem cells for psoriasis: a phase 1/2a, single-arm study.Signal transduction and targeted therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 8 institutions in 5 countries.
Funding
Abstract
Interleukin 10 (IL-10) is an antiinflammatory cytokine, but also promotes B cell responses and plays a pathogenic role in systemic lupus erythematosus (SLE). CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.